Isis Pharmaceuticals Gets $7.5M From Alnylam

Carlsbad-based Isis Pharmaceuticals said late Monday that it has received $7.5M in a payment from Alnylam Pharmaceuticals, as part of a recent alliance between Genzyme and Alnylam. According to the biotech marker, the deal also has the potential to give it royalties on products and a portion of future milestone payments. Isis said the latest deal brings its total generates from sales and licensing of its intellectual property to "well over" $400M. About $50M of that has been generated from Isis Pharmaceuticals' collaborations with Alnylam.